Contacts

Publication of the activity report and financial information for the first half-year (April – Sept. 2019)

December 3, 2019

• Progression of the portfolio with FDA IND clearance to initiate clinical activities for mdc-TJK and mdc-ANG entering preclinical
• Launch of Animal Health activities
• Revenue increase and strong cash position in line with expectations

Post-closing events
• Up to 19 M$ grant from the Bill & Melinda Gates Foundation for mdc-WWM
• Antipsychotic programs: confirmation of clinical activities start for the second long-acting injectable antipsychotic mdc-TJK and interim analysis for mdc-IRM Phase 3 in the second half of 2020

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.